LogicBio Therapeutics (LOGC) Provides Business Updates

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/28/2026

1. ORCL
2. BA
3. AVGO
4. CDNS
5. ANT
6. HOOD
7. SPY
8. STX
9. INTC
10. META

Go back to LogicBio Therapeutics (LOGC) Provides Business Updates

LogicBio Therapeutics Provides Business Updates

December 22, 2021 8:00 AM EST

LEXINGTON, Mass., Dec. 22, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage genetic medicine company, today provided updates around its SUNRISE Phase 1/2 clinical trial and development pipeline, and announced the appointment of Susan R. Kahn to its Board of Directors.

SUNRISE Phase 1/2 Clinical Trial Update

SUNRISE is a first-in-human, open-label, multi-center, Phase 1/2 clinical trial designed to assess the safety and tolerability of an intravenous infusion of LB-001, the company's investigational, single-administration genome editing therapy, in pediatric patients with methylmalonic acidemia (MMA). SUNRISE is... More